244 related articles for article (PubMed ID: 22144555)
21. Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals.
Fani M; Mansi R; Nicolas GP; Wild D
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267479
[TBL] [Abstract][Full Text] [Related]
22. Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides-Where Are We Now.
Naik M; Al-Nahhas A; Khan SR
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159027
[TBL] [Abstract][Full Text] [Related]
23. Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms.
Del Olmo-Garcia MI; Prado-Wohlwend S; Andres A; Soriano JM; Bello P; Merino-Torres JF
Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944626
[TBL] [Abstract][Full Text] [Related]
24. Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview.
Cimini A; Ricci M; Russo F; Egidi M; Calabria F; Bagnato A; Schillaci O; Chiaravalloti A
Pharmaceuticals (Basel); 2021 Aug; 14(9):. PubMed ID: 34577572
[TBL] [Abstract][Full Text] [Related]
25. Design, Synthesis, In Vitro and In Vivo Evaluation of Heterobivalent SiFA
Cheng X; Hübner R; von Kiedrowski V; Fricker G; Schirrmacher R; Wängler C; Wängler B
Pharmaceuticals (Basel); 2021 Jun; 14(6):. PubMed ID: 34200477
[TBL] [Abstract][Full Text] [Related]
26. Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy.
Hu Y; Ye Z; Wang F; Qin Y; Xu X; Yu X; Ji S
Front Endocrinol (Lausanne); 2021; 12():679000. PubMed ID: 34093445
[TBL] [Abstract][Full Text] [Related]
27. Synthesis of Novel, Dual-Targeting
Gyuricza B; Szabó JP; Arató V; Szücs D; Vágner A; Szikra D; Fekete A
Pharmaceutics; 2021 May; 13(6):. PubMed ID: 34073528
[TBL] [Abstract][Full Text] [Related]
28. Glypican-3 targeted delivery of
Labadie KP; Ludwig AD; Lehnert AL; Hamlin DK; Kenoyer AL; Sullivan KM; Daniel SK; Mihailovic TN; Sham JG; Orozco JJ; Yeung RS; Chen DL; Wilbur DS; Miyaoka RS; Park JO
Sci Rep; 2021 Feb; 11(1):3731. PubMed ID: 33580090
[TBL] [Abstract][Full Text] [Related]
29. New Frontiers in Molecular Imaging Using Peptide-Based Radiopharmaceuticals for Prostate Cancer.
Li X; Cai H; Wu X; Li L; Wu H; Tian R
Front Chem; 2020; 8():583309. PubMed ID: 33335885
[TBL] [Abstract][Full Text] [Related]
30. Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy.
Judmann B; Braun D; Wängler B; Schirrmacher R; Fricker G; Wängler C
Pharmaceuticals (Basel); 2020 Jul; 13(8):. PubMed ID: 32751666
[TBL] [Abstract][Full Text] [Related]
31. Radiopharmaceutical therapy in cancer: clinical advances and challenges.
Sgouros G; Bodei L; McDevitt MR; Nedrow JR
Nat Rev Drug Discov; 2020 Sep; 19(9):589-608. PubMed ID: 32728208
[TBL] [Abstract][Full Text] [Related]
32. PEGylated peptide to TIP1 is a novel targeting agent that binds specifically to various cancers in vivo.
Kapoor V; Singh AK; Rogers BE; Thotala D; Hallahan DE
J Control Release; 2019 Mar; 298():194-201. PubMed ID: 30763622
[TBL] [Abstract][Full Text] [Related]
33. Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas.
Leijon H; Remes S; Hagström J; Louhimo J; Mäenpää H; Schalin-Jäntti C; Miettinen M; Haglund C; Arola J
Hum Pathol; 2019 Apr; 86():66-75. PubMed ID: 30529752
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin receptor PET ligands - the next generation for clinical practice.
Pauwels E; Cleeren F; Bormans G; Deroose CM
Am J Nucl Med Mol Imaging; 2018; 8(5):311-331. PubMed ID: 30510849
[TBL] [Abstract][Full Text] [Related]
35. Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome.
Appay R; Tabouret E; Touat M; Carpentier C; Colin C; Ducray F; Idbaih A; Mokhtari K; Uro-Coste E; Dehais C; Figarella-Branger D;
Acta Neuropathol Commun; 2018 Sep; 6(1):89. PubMed ID: 30193580
[TBL] [Abstract][Full Text] [Related]
36. Upcoming imaging concepts and their impact on treatment planning and treatment response in radiation oncology.
Roberts PR; Jani AB; Packianathan S; Albert A; Bhandari R; Vijayakumar S
Radiat Oncol; 2018 Aug; 13(1):146. PubMed ID: 30103786
[TBL] [Abstract][Full Text] [Related]
37.
Taralli S; Sollini M; Milella M; Perotti G; Filice A; Menga M; Versari A; Rufini V
EJNMMI Res; 2018 Jul; 8(1):64. PubMed ID: 30032450
[TBL] [Abstract][Full Text] [Related]
38. From Carbon-11-Labeled Amino Acids to Peptides in Positron Emission Tomography: the Synthesis and Clinical Application.
Pekošak A; Filp U; Poot AJ; Windhorst AD
Mol Imaging Biol; 2018 Aug; 20(4):510-532. PubMed ID: 29411226
[TBL] [Abstract][Full Text] [Related]
39. Targeting aggressive prostate cancer-associated CD44v6 using phage display selected peptides.
Peng Y; Prater AR; Deutscher SL
Oncotarget; 2017 Oct; 8(49):86747-86768. PubMed ID: 29156833
[TBL] [Abstract][Full Text] [Related]
40. Labelling of
Iori M; Capponi PC; Rubagotti S; Esposizione LR; Seemann J; Pitzschler R; Dreger T; Formisano D; Grassi E; Fioroni F; Versari A; Asti M
Contrast Media Mol Imaging; 2017; 2017():8160134. PubMed ID: 29097938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
